Next Article in Journal
Circular RNAs: Potential Applications as Therapeutic Targets and Biomarkers in Breast Cancer
Previous Article in Journal
Human Cytomegalovirus-Encoded microRNAs Can Be Found in Saliva Samples from Renal Transplant Recipients
Article

Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma

1
Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, DK-2450 Copenhagen, Denmark
2
Department of Clinical Medicine, Faculty of Medicine, Aalborg University, DK-9000 Aalborg, Denmark
3
Department of Haematology, Clinical Cancer Research Center, Aalborg University Hospital, DK-9000 Aalborg, Denmark
*
Authors to whom correspondence should be addressed.
Non-Coding RNA 2021, 7(1), 1; https://doi.org/10.3390/ncrna7010001
Received: 28 October 2020 / Revised: 21 December 2020 / Accepted: 24 December 2020 / Published: 28 December 2020
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults. Although significant progress has been made in recent years to treat DLBCL patients, 30%–40% of the patients eventually relapse or are refractory to first line treatment, calling for better therapeutic strategies for DLBCL. Long non-coding RNAs (lncRNAs) have emerged as a highly diverse group of non-protein coding transcripts with intriguing molecular functions in human disease, including cancer. Here, we review the current understanding of lncRNAs in the pathogenesis and progression of DLBCL to provide an overview of the field. As the current knowledge of lncRNAs in DLBCL is still in its infancy, we provide molecular signatures of lncRNAs in DLBCL cell lines to assist further lncRNA research in DLBCL. View Full-Text
Keywords: DLBCL; lncRNA; miRNA; rituximab DLBCL; lncRNA; miRNA; rituximab
Show Figures

Figure 1

  • Supplementary File 1:

    ZIP-Document (ZIP, 52 KiB)

  • Externally hosted supplementary file 1
    Doi: 10.5281/zenodo.4146742
    Link: https://doi.org/10.5281/zenodo.4146742
    Description: Supplementary Table S1: List of differentially expressed lncRNAs in rituximab-resistant compared to -sensitive DLCBL cell lines (n = 3 biologically independent samples with the threshold values of 2-fold and P < 0.05). Supplementary Table S2: List of differentially expressed transcription factors and their binding to the promoter regions of differentially expressed lncRNAs. Supplementary Table S3: List of expressed RBPs and their binding to the up-regulated lncRNAs. Each number indicates the number of binding sites predicted to bound by each RBP shown.
MDPI and ACS Style

Karstensen, K.T.; Schein, A.; Petri, A.; Bøgsted, M.; Dybkær, K.; Uchida, S.; Kauppinen, S. Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma. Non-Coding RNA 2021, 7, 1. https://doi.org/10.3390/ncrna7010001

AMA Style

Karstensen KT, Schein A, Petri A, Bøgsted M, Dybkær K, Uchida S, Kauppinen S. Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma. Non-Coding RNA. 2021; 7(1):1. https://doi.org/10.3390/ncrna7010001

Chicago/Turabian Style

Karstensen, Kasper T., Aleks Schein, Andreas Petri, Martin Bøgsted, Karen Dybkær, Shizuka Uchida, and Sakari Kauppinen. 2021. "Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma" Non-Coding RNA 7, no. 1: 1. https://doi.org/10.3390/ncrna7010001

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop